Effect of Captopril on GLS in Duchenne Myodystrophy
Launched by AIN SHAMS UNIVERSITY · Jun 27, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called Captopril on heart function in boys with Duchenne muscular dystrophy (DMD). Specifically, it aims to see how Captopril can help improve a measure of heart function known as Global Longitudinal Strain (GLS) over time. The trial is currently looking for boys aged 6 years and older who have been genetically diagnosed with DMD and have a GLS measurement that is lower than -18%.
Participants who join this study will receive Captopril in addition to their regular treatment. They will be closely monitored to see how their heart function changes with this medication. It’s important to note that some boys may not be eligible if they have certain health conditions, such as problems with their kidneys or heart function. If you're considering participating, you’ll need to provide your consent and discuss any potential risks with your doctor. This study could provide valuable information on improving heart health in DMD patients.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS \< -18% with minimum age of 6 years old.
- Exclusion Criteria:
- • Any patient who refuses to sign an informed consent.
- • Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
- • Reduced ejection fraction below 50%.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Mona Mostafa Rayan, MD
Principal Investigator
Professor of cardiology -Ain Shams university
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported